| Name | Title | Contact Details |
|---|
Prevention Point Philadelphia is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lifespire's Day Treatment facilities provide state of the art therapeutic services for people with severe cognitive and physical challenges. The emphasis of Lifespire's coordinated therapeutic approach is to first assess each person's needs, preferences,
CODAC Behavioral Health Services of Pima County is a nonprofit 501(c)(3) organization that provides mental health and substance use disorder treatment and prevention programs to children, adults and families in Pima County. It is CODAC’s mission to work collaboratively with individuals, families and organizations to eliminate the harmful effects of substance use disorders, mental illness and abuse on their lives and families. CODAC was founded in 1970 and has evolved into a comprehensive service provider with a full continuum of mental health and substance use disorder treatment programs for youth (ages 12-17), young adults (ages 18-21) and adults (ages 22+) and their families at 10 conveniently located sites. CODAC’s prevention services are community-based and recognized as best-practices for preventing risky behaviors in Pima County youth and families.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
OneLegacy is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.